Merit Medical Systems, Inc. (MMSI) stock analysis
Healthcare · Medical Instruments & Supplies
From the 10-K filed 2026-02-24
How it makes money
Cardiovascular sales reached $1.443 billion in 2025, while gross profit reached 48.7% of total sales.
Revenue is dominated by the cardiovascular segment, which provides specialized devices for peripheral and cardiac interventions. Healthcare facilities pay for these products because they provide critical access and treatment for arterial and vascular diseases.
Profitability is driven by the mix of proprietary devices and custom procedural solutions, such as kits and trays configured for specific facility workflows. The acquisition of hemostatic brands like StatSeal and WoundSeal also contributes to the margin profile.
What protects it: the moat
It maintains margins through patented hemostatic technologies and providing facility-unique procedural kits that are difficult for competitors to replicate without equivalent product breadth.
The company relies on a portfolio of proprietary products including the Wrapsody endoprosthesis and the HeRO Graft to maintain long-term vessel patency in dialysis patients. These specialized tools, combined with patented hemostatic devices, create high switching costs for clinical teams accustomed to these specific solutions.
Management claims that providing custom procedural solutions tailored to hospital requests further embeds its products within the medical facility's operational infrastructure.
What growth costs
It spent resources acquiring the C2 CryoBalloon device and Biolife technologies to drive its Continued Growth initiatives program through 2026.
The company utilizes strategic acquisitions to expand its product lines and geographic reach. In 2025, it completed the Biolife merger and acquired the C2 CryoBalloon technology from Pentax to bolster its endoscopy and cardiovascular offerings.
Maintaining these earnings requires continuous investment in research and development, which accounted for 6.4% of sales in 2025, and operational discipline to meet multi-year financial targets.
What could damage it
Reliance on a small number of sterilization providers means that if one service provider stops operations, the company may be unable to find a replacement.
The manufacturing process depends on a restricted number of external service providers for product sterilization. Any regulatory failure or operational cessation at these providers would halt the distribution of finished medical devices.
Additionally, many products require petroleum-based resins. Volatility in oil prices or supply interruptions from a limited number of resin suppliers could simultaneously increase costs and prevent the company from manufacturing core product lines.
About Merit Medical Systems, Inc.
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; kits and accessories for endoscopy and bronchoscopy procedures; and temporary pacing technology. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.